{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', \"analysis process for COOLIEF* is performed in accordance with industry standards for 'Risk Management\", \"for Medical Devices' and ensures that the level of risk is acceptable prior to starting the clinical study.\", 'The potential risks to subjects in which a radiofrequency neurotomy procedure is performed, regardless of', 'the treatment modality, may include the following, all of which are anticipated adverse events that have', 'been identified as possible complications of procedures involving lesioning of nervous tissue:', 'Infection,', 'Damage to collateral nervous tissue,', 'Increased pain,', 'Visceral injury,', 'Failure of technique,', 'Superficial burns;', 'Damage to collateral tissue (i.e., bruising or hematoma),', 'Deafferentation dysesthesiae', 'Paralysis, and', 'Death', 'The potential risks specifically associated with the use of COOLIEF* for radiofrequency neurotomy are', 'anticipated to be the same as those listed above, with the exception of visceral injury and paralysis, as', 'the device will not be used in any anatomic location in this study other than the index knee.', 'As described in Appendix 2, the potential benefits of single injection of Hyaluronic Acid (Hylan G-F 20)', 'include short to medium term pain relief, assistance with therapeutic exercise, and some restoration of', 'function.', 'Hylan injection involves inserting a needle directly into the space inside your knee. This procedure', 'carries certain risks, including:', 'Arthralgia', 'Arthritis', 'Arthropathy', 'Gait disturbance', 'Injection site pain', 'Joint effusion', 'Joint stiffness', 'Joint swelling', 'Joint warmth', 'Version #: 4.0', 'Page 16 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', 'There are other Hylan products on the market which have reported the following risks:', 'Rash', 'Hives', 'Itching', 'Fever', 'Nausea', 'Headache', 'Dizziness', 'Chills', 'Muscle cramps', 'Paresthesia', 'Peripheral edema', 'Malaise', 'Respiratory difficulties', 'Flushing', 'Facial swelling', '5', 'STUDY OBJECTIVES', 'This study is designed to:', 'Determine the effectiveness (primarily measured by pain relief) of COOLIEF * when used to', 'create radiofrequency lesions of the genicular nerves compared to pain relief following a single', 'injection of Hyaluronic Acid (Hylan G-F 20); and', 'Confirm the safety of COOLIEF * when used to perform radiofrequency lesions of the genicular', 'nerves in subjects to manage knee pain compared to safety of single injection of Hyaluronic Acid', '(Hylan G-F 20).', 'To describe the long term clinical effects (such as current level of pain, function, and progression', 'of disease through 24 months) for patients who initially randomized to and received CRFA for', 'treatment of their OA knee pain.', '6', 'INVESTIGATIONAL PLAN', '6.1', 'STUDY DESIGN', 'This is a prospective, randomized, multicenter comparison study examining the outcomes of subjects with', 'OA and knee pain undergoing a procedure to create a radiofrequency lesion of the genicular nerves with', 'the CRFA system compared to subjects receiving HA. A total of approximately 168 subjects will be', 'enrolled into this study, with subjects undergoing either CRFA or HA injection in a 1:1 randomization', 'scheme. Follow up will be conducted for a total of 12-months post randomized procedure with the', 'Version #: 4.0', 'Page 17 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', 'primary endpoint being completed at month 6. Subjects randomized to the comparison (HA) group will', 'have the option to cross over to the neurotomy group after completing the 6-month endpoint assessment.', 'They would then be followed for an additional 6 months. Pain, overall outcome, quality of life, pain', 'medication use, and adverse events will be compared between the two treatment groups in order to', 'determine success. Unless they have received an additional procedure on their index knee, subjects who', 'were randomized to and received CRFA as their initial treatment will have the option to add 2 additional', 'visits at 6-month intervals, representing 18 and 24 months post initial treatment.', 'PRIMARY', 'Secondary', 'Extension Study', 'Visit 2: CRFA', 'Visit 3:', 'Visit 4:', 'Visit 5:', 'Visit 6:', 'Visit 7:', 'Visit 8:', 'ACTIVE GROUP', 'Treatment', '1 Mo', 'Mo', 'Mo', '12M', '18 Mo', '24 Mo', 'Visit (Day 0)', 'Visit 1: Screening', 'Blocks', 'and Randomization', 'Visit 5A:', 'CRFA', 'Visit 5B:', 'Visit 5C:', 'Visit 6:', 'Treatment', 'Mo', '3Mo', '6 Mo', 'Visit HA', 'Visit (Day 0)', 'Visit 3:', 'Visit 4:', 'Visit 5:', 'CONTROL GROUP', 'Treatment', 'Mo', 'Mo', '6 Mo', 'Visit (Day 0)', 'Visit 6:', '(No', 'Crossover)', '12 Mo', 'Actual', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20 21', '22', '23', '24', 'Month', 'CRFA = Genicular Neurotomy using Cooled Radiofrequency Ablation', 'HA = Hyaluronic Acid Injection (Synvisc-One 6 mL injection)', '6.2', 'ENDPOINTS', '6.2.1', 'Primary Endpoints', 'Primary Effectiveness Endpoint:', 'The proportion of subjects whose knee pain is reduced by > 50% based on the NRS scale at 6 Months.', 'Primary Safety Endpoint:', 'The proportion of subjects experiencing adverse events through final follow up.', '6.2.2', 'Secondary Endpoints', 'Secondary Effectiveness Endpoints:', 'The proportion of subjects whose knee pain is reduced from baseline by > 50% based on the', 'NRS at 12 months.', 'The change in WOMAC score from baseline to the 6 month visit and 12 month visit.', '6.2.3', 'Tertiary Endpoints', 'Tertiary effectiveness endpoint 1: The change in measured EQ-5D-5L scale from baseline at the', '6-month visit and 12-month visit.', 'Tertiary effectiveness endpoint 2: The measured Global Perceived Effect scale at the 6-month', 'visit and 12-month visit.', 'Version #: 4.0', 'Page 18 of 62', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}